Abstract
Safety of Sunitinib, a novel tyrosine kinase inhibitor of vascular endothelial growth receptor, has not been reported in metastatic renal cell carcinoma (RCC) in the background of chronic kidney disease (CKD) among Indian patients. We report the first case of a 79-year-old Indian male patient on chronic dialysis presenting with metastatic renal carcinoma. During the course of dialysis managed with low-dose Sunitinib (25mg) per day for 4 weeks out of every 6-week regimen, the patient did not experience common adverse effects of Sunitinib like hypertension and hepatotoxicity, but improved on clinical parameters. The patient was managed well for the next 16 months until he succumbed to septicemic pneumonitis. Sunitinib can be safely used in metastatic RCC in the background of CKD among the Indian patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
